STOCK TITAN

Adamis Pharmaceuticals (ADMP) Stock News, Feb-Jun 2021

ADMP NASDAQ
Rhea-AI Summary

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced significant updates regarding its product pipeline. The company has resubmitted its NDA for ZIMHI, a naloxone injection for opioid overdose, to the FDA and is awaiting a response. Additionally, Adamis is preparing to begin patient enrollment for a Phase 2/3 trial of Tempol, aimed at treating COVID-19. The company's epinephrine product, SYMJEPI, has seen a 90% increase in unit sales since transitioning commercial partners.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
Rhea-AI Summary

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it received a notification from NASDAQ for failing to file its 10-Q for Q1 2021. As a result, the company is not compliant with NASDAQ Rule 5250(c)(1), which mandates timely filings. Adamis has 60 days to submit a plan to regain compliance, with the possibility of a 180-day extension if accepted. If the plan is rejected, Adamis can appeal to the NASDAQ Hearings Panel. This notice has no immediate impact on the listing of ADMP's stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
Rhea-AI Summary

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has postponed its investor conference call originally set for May 17, 2021, due to a delay in filing its Quarterly Report (Form 10-Q) for Q1 2021. The company filed a Form 12b-25 with the SEC to extend the filing deadline by five days, as allowed under Rule 12b-25 of the Securities Exchange Act of 1934. A new date for the conference call will be announced soon. Adamis focuses on developing biopharmaceutical products for various therapeutic areas, including allergy and respiratory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
conferences earnings
Rhea-AI Summary

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has resubmitted its New Drug Application (NDA) for ZIMHI™, a high-dose naloxone injection intended for opioid overdose treatment, to the FDA. This follows feedback from a Type A meeting held in April. The CEO, Dr. Dennis J. Carlo, expressed confidence that the new submission addresses previous concerns raised in a November 2020 Complete Response Letter. ZIMHI aims to provide an effective alternative in the market for naloxone products, potentially saving lives during the ongoing opioid crisis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
-
Rhea-AI Summary

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) will host an investor conference call on May 17, 2021, at 2 p.m. PT to discuss its Q1 2021 financial results and provide a business update. The press release with these results will be available after 1 p.m. PT on the same day. During the call, Dennis J. Carlo, Ph.D., along with the management team, will cover recent developments, quarterly events, and future goals. A live audio webcast will be accessible, with a replay offered post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
conferences earnings date
-
Rhea-AI Summary

Adamis Pharmaceuticals (NASDAQ: ADMP) announced its financial results for the year ended December 31, 2020, reporting total revenues of $16.5 million, down from $22.1 million in 2019. The company plans to advance its pipeline, including resubmitting the NDA for ZIMHI and initiating a Phase 2/3 trial for Tempol in COVID-19 patients by Q2 2021. A recent public offering raised approximately $48.6 million, providing financial support for operations. Adamis expects transformative growth in 2021, driven by product launches and partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
Rhea-AI Summary

Adamis Pharmaceuticals (NASDAQ: ADMP) announced an investor conference call on April 15, 2021, at 2 p.m. PT to discuss its fourth-quarter and full-year 2020 financial results. The press release with these results will be available post 1 p.m. PT on the same day. The call will provide insights into the company's recent developments and future goals. Dennis J. Carlo, President and CEO, will lead the discussion, and a live audio webcast will be accessible.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
conferences earnings date
-
Rhea-AI Summary

Adamis Pharmaceuticals (NASDAQ: ADMP) provided an update regarding its New Drug Application (NDA) for ZIMHI™, a high-dose naloxone injection for opioid overdose treatment. Following a Type A meeting with the FDA, Adamis plans to resubmit the NDA within 45 days, pending no delays. The FDA indicated a commitment to expedite the review as the opioid crisis escalates. CEO Dr. Dennis J. Carlo highlighted the urgency, noting a significant rise in overdose deaths, emphasizing ZIMHI's potential to save lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
none
-
Rhea-AI Summary

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) announced significant findings from studies at the University of Texas Medical Branch, revealing that Tempol, a novel antioxidant, effectively reduces lung inflammation in COVID-19 challenged hamsters. This marks the first data confirming Tempol's anti-inflammatory properties in this context. The company plans to submit findings for peer review and is preparing for a Phase 2/3 clinical trial to evaluate Tempol's safety and efficacy in early COVID-19 patients. The trial aims to assess how Tempol affects inflammation markers and hospitalization rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
covid-19
Rhea-AI Summary

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) received FDA clearance to commence a clinical trial for Tempol as a treatment for COVID-19. The study, titled "A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study," aims to evaluate Tempol's safety and effectiveness in reducing hospitalization rates among early COVID-19 patients. Tempol has shown potential benefits such as reducing pro-inflammatory cytokines and platelet aggregation. The CEO underscores the urgency for new COVID-19 therapies as virus mutations pose risks to current treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
covid-19